



INTRODUCING
A UNIQUE
JOINT-VENTURE PROJECT

CANQURA
ONCOLOGY



Q-VANT BIOSCIENCES™
Next-generation sustainable saponins for pharmaceuticals


RESEARCH
FOR
LIFE

NOVEL CANCER TREATMENTS

Project:

Phase 1 / 2 trials for
AML, PROSTATE, RENAL

CURRENT MARKET OVERVIEW



\$1.3 BILLION

AML – ACUTE MYELOID LEUKAEMIA

THE GLOBAL AML MARKET GREW FROM \$1.15B TO \$1.29B IN 2023 AT (CAGR) OF 12.38%. THE MARKET SIZE OF AML IS EXPECTED TO GROW TO \$2.03B IN 2027 AT CAGR OF 12.03%

\$6.4 BILLION

RENAL CANCER

THE RENAL CANCER DRUG MARKET IS EXPECTED TO REACH \$6.4 BILLION BY 2030 AT 5,50% CAGR DURING THE FORECAST PERIOD 2022-2023.

\$13 BILLION

PROSTATE CANCER

THE MARKET SIZE IN 2023 IS EXPECTED TO REACH \$12.98 BILLION IN 2023 AND TO \$27.51 BILLION IN 2032 AT A CAGR OF 8.75%

ABOUT CANQURA

Canqura AB (Ltd) is a Swedish based company which specializes within the Oncology area, with primary focus on, but not limited to, the AML area.

With several patents in strategic countries and continents, the owners of the company have decided to explore the possibilities to offer larger companies to acquire the company.

In 2011, a group of entrepreneurs invested in a philanthropic effort to treat cancer via this discovery. Together with the inventor of the original ISCOM technology, the group created a business structure, bringing in additional expertise and founded several companies focused to exploiting the patent portfolio in cancer therapy.

ABOUT Q-VANT

Q-VANT Biosciences is a privately-held company that has solved the supply chain problem of QS-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets.

The company's disruptive technology increases the potential for sustainable QS-21 supply by a factor of 1,000 resulting in a possible annual production capacity exceeding 20 billion pharmaceutical doses.

THE PARTNERS

CANQURA (Shareholder)

PATENT AND RIGHTS HOLDER

Owns the formulations for Fracturized QS7 and QS21 stabilized products and the rights for the use of G2 and G3 versions of this technology in the treatment of cancer. <https://www.canqura.com>

Q-Vant (Shareholder)

SUPPLIER OF GMP Q21 FRACTIONS

The company's disruptive technology produces sustainable QS-21 supply from new state of the art facilities in Chile. Able to formulate Canqura products QURA 100 / 200
<https://q-vant.com/>

SEEKING INVESTMENT

Collaborator – CRO, R&D Centre etc

Parties with active ability to conduct and conclude Phase 1/2 trials for the establishment of proof and take this project to exit stage which will be either sale to producer/market or to take over and benefit from end use themselves.


VC or Non collaborative

Investment from VC investment “angels” with an eye on the potential substantial ROI if successful.

TIME PLAN AND CLINICAL COSTS

PRODUCT	FORMULATION	PRE-CLINICAL	PHASE I/II	PHASE 3	PHASE 4/5
QVANT	ARDENA	CHARLES RIVER	ALLUCENT	ALLUCENT	TBC
	\$1,900,000	\$200,000	\$18,000,000	\$400,000	\$tbc
	9 months	4 months	46 months	6 months	


FUNDING



\$2,400,000

MILESTONE 1


Months
1-9



\$665,000

MILESTONE 2


Months
10-14



\$9,500,000

MILESTONE 3

Months
15-38




\$9,500,000

MILESTONE 4

Months
39-62

ABOUT THE PRODUCT


Saponin-based G3 nanoparticles – with dual action



1. Stops cancer cell replication

Inhibited cell replication
Reprogramming
Cell differentiation
Apoptosis

CANQURA
ONCOLOGY



2. Immuno-modulatory effects

Innate immune responses

- Cytokine production (IL-12) by monocytes
- Activation of APCs with improved tumor antigen presentation and NK cell activation

Acquired immune responses

- Antibody production by B-cells
- Cell-mediated immunity through CTL response
- IFN- γ production by Th cells

PRODUCT BENEFITS

Normal cells replicate around 30 times then enter apoptosis (die).

Cancer affected cells continue with replication limiting healthy cell growth, eventually killing the healthy cells.

CANQURA targets ONLY the cancer affected cells and re-programmes them to revert to a normal cycle and then to apoptosis.



VIDEO



PRODUCT OVERVIEW

CANQURA
ONCOLOGY



UNIQUE

Only targets cancers cells, leaving healthy cells unharmed

FIRST TO MARKET

Using nano technology within the oncology field

TESTED

A “new-use” product currently used within vaccination

AUTHENTIC

Easily adaptable to many variants of cancer forms

COMFORTABLE

Works with virtually no side effects potentially. A step change from current treatment

PATENTS

The patent portfolio consists of the “Killcan” family which derives from the PCT application WO 2008/063129 filed in 2007, and the “G3” EP application which derives from WO 2013/051994 filed in 2012. Both application families relate to the use of certain (nano)particles in cancer therapy. The inventions described in the two application families mainly differ in the way the (nano)particles have been defined (i.e. what they contain and their morphology). ISCOMs and G3 differ mainly in their size and inner structure and have both proved efficient against solid and non-solid cancer tumors in vitro. The patents rights cover Europe, USA, Canada, Australia, China and Japan.

Duecom-Killcan


The “Killcan” family members (EP, US, CA, AU, CN and JP) have all been granted. It covers the use of ISCOM matrix particles in cancer treatment, and in some specific markets these patents more broadly cover the use in cancer treatment of particles of any shape or composition, as long as the particles contain at least one lipid and at least one saponin and does not contain a cancer antigen.

Canqura-G3

The Canqura patent portfolio relate to certain nanoparticles (named ISCOMs and G3) which are based i.a. on Quillaja saponins. Canqura holds the exclusive patent rights to the use of these particles in cancer treatment. In addition, despite G3 product patents having been sold for vaccine use, Canqura holds an agreement regulating all rights for cancer applications as granted within the patents.

The “G3” EP application has been granted (2023-01-04) and given the European patent No. EP3311827

ORGANISATION STRUCTURE



FINANCIALS



	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	SUM
MILESTONES							
Fractioning	200 000						200 000
Formulation	1 900 000						1 900 000
Pre Clinical		400 000					400 000
Clinical Studies I/IIa			4 500 000	4 500 000	4 500 000	4 500 000	18 000 000
CLINICAL COSTS	2 100 000	400 000	4 500 000	4 500 000	4 500 000	4 500 000	20 500 000
OPERATIONS							
Management	200 000	200 000	200 000	200 000	200 000	200 000	1 200 000
Patents	30 000	30 000	30 000	30 000	30 000	30 000	180 000
Travel	20 000	20 000	20 000	20 000	20 000	20 000	120 000
Other	15 000	15 000	15 000	15 000	15 000	15 000	90 000
TOTAL EXPENSES	265 000	265 000	265 000	265 000	265 000	265 000	1 590 000
SUM	2 365 000	665 000	4 765 000	4 765 000	4 765 000	4 765 000	22 090 000



CANQURA
ONCOLOGY



THANK YOU

WWW.CANQURA.COM